Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy.
Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy.
复制标题
肌力感应LIM蛋白在人类家族性肥厚型心肌病肌瘤生物力学信号传导中的作用
DOI：
10.1161/circulationaha.121.056265
复制
发表时间：
2022-04-19
期刊：
影响因子：
37.8
通讯作者：
Qyang, Yibing
中科院分区：
文献类型：
--
作者：
Riaz, Muhammad;Park, Jinkyu;Sewanan, Lorenzo R.;Ren, Yongming;Schwan, Jonas;Das, Subhash K.;Pomianowski, Pawel T.;Huang, Yan;Ellis, Matthew W.;Luo, Jiesi;Liu, Juli;Song, Loujin;Chen, I-Ping;Qiu, Caihong;Yazawa, Masayuki;Tellides, George;Hwa, John;Young, Lawrence H.;Yang, Lei;Marboe, Charles C.;Jacoby, Daniel L.;Campbell, Stuart G.;Qyang, Yibing
关键词：
Familial hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and is typically caused by mutations in genes encoding sarcomeric proteins that regulate cardiac contractility. HCM manifestations include left ventricular hypertrophy and heart failure, arrythmias, and sudden cardiac death. How dysregulated sarcomeric force production is sensed and leads to pathological remodeling remains poorly understood in HCM, thereby inhibiting the efficient development of new therapeutics. Our discovery was based on insights from a severe phenotype of an individual with HCM and a second genetic alteration in a sarcomeric mechanosensing protein. We derived cardiomyocytes from patient-specific induced pluripotent stem cells (iPSC-CMs) and developed robust engineered heart tissues (EHTs) by seeding iPSC-CMs into a laser-cut scaffold possessing native cardiac fiber alignment in order to study human cardiac mechanobiology at both cellular and tissue levels. Coupled with computational modeling for muscle contraction and rescue of disease phenotype via gene editing and pharmacological interventions, we have identified a new mechanotransduction pathway in HCM, shown to be essential in modulating the phenotypic expression of HCM in five families bearing distinct sarcomeric mutations. Enhanced actomyosin crossbridge formation caused by sarcomeric mutations in cardiac myosin heavy chain (MYH7) led to increased force generation, which when coupled with slower twitch relaxation, destabilized the muscle LIM protein (MLP) stretch-sensing complex at the Z-disc. Subsequent reduction in the sarcomeric MLP level caused disinhibition of calcineurin–nuclear factor of activated T-cells (NFAT) signaling, which promoted cardiac hypertrophy. We demonstrate that the common MLP-W4R variant is an important modifier, exacerbating the phenotypic expression of HCM, but alone may not be a disease-causing mutation. By mitigating enhanced actomyosin crossbridge formation through either genetic or pharmacological means, we alleviated stress at the Z-disc, preventing the development of hypertrophy associated with sarcomeric mutations. Our studies have uncovered a novel biomechanical mechanism through which dysregulated sarcomeric force production is sensed and leads to pathological signaling, remodeling, and hypertrophic responses. Together, these establish the foundation for developing innovative mechanism-based treatments for HCM that stabilize the Z-disc MLP mechanosensory complex.
